Imatinib
Information
- Drug Name
- Imatinib
- Description
- Entry(CIViC)
- 127
CIViC
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04578847 | Active, not recruiting | Phase 2 | A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) | January 15, 2020 | January 15, 2025 |
| NCT03654768 | Active, not recruiting | Phase 2 | Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia | October 24, 2018 | July 1, 2028 |
| NCT02881086 | Active, not recruiting | Phase 3 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | August 2016 | July 2025 |
| NCT03722420 | Active, not recruiting | Phase 3 | Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) | December 28, 2018 | June 30, 2025 |
| NCT04971226 | Active, not recruiting | Phase 3 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | October 6, 2021 | January 18, 2028 |
| NCT03193281 | Active, not recruiting | Phase 2 | KISS Study: Kinase Inhibition With Sprycel Start up | July 17, 2017 | December 31, 2025 |
| NCT02365441 | Active, not recruiting | Phase 2 | A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) | June 30, 2015 | December 31, 2023 |
| NCT03578367 | Active, not recruiting | Phase 2 | Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | November 22, 2018 | February 6, 2025 |
| NCT03589326 | Active, not recruiting | Phase 3 | A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | October 4, 2018 | July 31, 2027 |
| NCT03906292 | Active, not recruiting | Phase 2 | Frontline Asciminib Combination in Chronic Phase CML | August 19, 2019 | December 2027 |
| NCT04070443 | Active, not recruiting | Phase 2 | Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase | November 13, 2019 | June 1, 2029 |
| NCT00476190 | Active, not recruiting | Phase 2 | ALL Adult Consortium Trial: Adult ALL Trial | April 2007 | December 2024 |
| NCT04138381 | Active, not recruiting | Phase 1/Phase 2 | Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST) | August 16, 2019 | April 16, 2023 |
| NCT02413736 | Active, not recruiting | Phase 3 | Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST | May 2015 | May 2033 |
| NCT04330690 | Active, not recruiting | Phase 3 | Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial | March 18, 2020 | May 18, 2024 |
| NCT01541709 | Active, not recruiting | Phase 2 | Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI | March 2012 | December 31, 2024 |
| NCT04394416 | Active, not recruiting | Phase 3 | Trial of Imatinib for Hospitalized Adults With COVID-19 | June 2, 2020 | December 30, 2024 |
| NCT02272777 | Completed | Phase 3 | A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase | July 17, 2014 | January 30, 2017 |
| NCT00079313 | Completed | Phase 2 | Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia | January 14, 2004 | October 25, 2010 |
| NCT03885830 | Completed | Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients | June 20, 2019 | June 15, 2022 | |
| NCT03891901 | Completed | Phase 2 | A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin | October 27, 2020 | August 30, 2022 |
| NCT00376467 | Completed | Phase 2 | STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia | December 2001 | February 2011 |
| NCT00390156 | Completed | Phase 1 | Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors | August 2006 | January 2011 |
| NCT00116935 | Completed | Phase 3 | Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) | February 2004 | December 2010 |
| NCT00130195 | Completed | Phase 2 | Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | September 2002 | May 2008 |
| NCT00420043 | Completed | Phase 1 | Effect of Food on Bioavailability of Modified Release Formulations of Imatinib | September 2006 | November 2006 |
| NCT00422825 | Completed | Phase 1 | Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib | June 2006 | September 2006 |
| NCT00424515 | Completed | Phase 2 | Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma | July 2006 | July 2011 |
| NCT00426179 | Completed | Phase 1/Phase 2 | Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen | December 2006 | August 2007 |
| NCT00471497 | Completed | Phase 3 | A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | July 31, 2007 | August 21, 2019 |
| NCT00481247 | Completed | Phase 3 | A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia | September 2007 | December 2015 |
| NCT00512902 | Completed | Phase 1/Phase 2 | A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis | August 2007 | December 2008 |
| NCT00150072 | Completed | Phase 2 | Efficacy and Safety of Imatinib in Chordoma | October 2004 | April 2008 |
| NCT00574873 | Completed | Phase 3 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | February 5, 2008 | May 27, 2015 |
| NCT01151852 | Completed | Phase 3 | Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT | June 2010 | March 2013 |
| NCT01188278 | Completed | Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey | July 2010 | January 2013 | |
| NCT01275196 | Completed | Phase 3 | Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients | April 2011 | October 2014 |
| NCT01319981 | Completed | Phase 2 | Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia | March 5, 2013 | November 11, 2020 |
| NCT01392469 | Completed | Phase 3 | Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants | April 20, 2011 | October 25, 2012 |
| NCT00193258 | Completed | Phase 1/Phase 2 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | June 2004 | August 2011 |
| NCT01404715 | Completed | Phase 1 | Drug-drug Interaction Study With Metformin and Imatinib | October 2011 | March 2013 |
| NCT01460693 | Completed | Phase 3 | Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia | August 2008 | March 7, 2018 |
| NCT01475110 | Completed | Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib | September 13, 2012 | November 24, 2016 | |
| NCT01511289 | Completed | Phase 3 | Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | August 2011 | |
| NCT01593254 | Completed | Phase 2 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib | September 12, 2012 | April 12, 2022 |
| NCT02081378 | Completed | Phase 1 | A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | April 24, 2014 | March 14, 2023 |
| NCT02130557 | Completed | Phase 3 | A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | July 15, 2014 | April 17, 2020 |
| NCT00193349 | Completed | Phase 2 | Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer | September 2002 | December 2007 |
| NCT03454503 | Completed | Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt | May 13, 2018 | December 28, 2020 | |
| NCT05286528 | Completed | Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | November 18, 2020 | January 31, 2022 | |
| NCT02352558 | Completed | Phase 1 | A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies | May 2015 | May 16, 2019 |
| NCT00237120 | Completed | Phase 3 | Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase) | November 2002 | June 2007 |
| NCT02480608 | Completed | Phase 1/Phase 2 | Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004) | April 2004 | May 2013 |
| NCT02495519 | Completed | Phase 2 | A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis) | April 2014 | June 2018 |
| NCT00103844 | Completed | Phase 2 | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia | February 2005 | March 2008 |
| NCT02977312 | Completed | Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan | August 2012 | February 2015 | |
| NCT03112603 | Completed | Phase 3 | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) | June 29, 2017 | December 15, 2022 |
| NCT03170180 | Completed | Phase 2 | Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer | March 1, 2017 | December 28, 2021 |
| NCT03328117 | Completed | Phase 1 | A Study to Investigate the Effects of Imatinib on Pulmonary Vascular Dysfunction in a Human Model of Lung Injury | November 13, 2017 | March 5, 2018 |
| NCT00632255 | Completed | Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment | January 2008 | May 2009 | |
| NCT00707408 | Completed | Phase 2 | High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML) | February 2004 | January 2009 |
| NCT00154336 | Completed | Phase 2 | A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis. | July 2004 | August 2005 |
| NCT00760877 | Completed | Phase 3 | Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) | June 2009 | July 2015 |
| NCT00760981 | Completed | Phase 1 | A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease | September 2008 | April 2012 |
| NCT00787384 | Completed | Phase 2 | Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes | October 2004 | December 2007 |
| NCT00802841 | Completed | Phase 3 | Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib | May 2009 | July 2014 |
| NCT00852566 | Completed | Phase 2 | Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia | March 2009 | December 2015 |
| NCT00858806 | Completed | Phase 2 | Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy | April 2008 | December 2014 |
| NCT00940563 | Completed | Phase 2 | A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors | March 2002 | |
| NCT00973752 | Completed | Phase 2 | Treatment of Older Adults With Acute Lymphoblastic Leukemia | August 2009 | April 2016 |
| NCT00982488 | Completed | Phase 2 | Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | October 2007 | December 2014 |
| NCT01025505 | Completed | Phase 2 | Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study | June 2012 | September 1, 2020 |
| NCT01048320 | Completed | Phase 1 | Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer | July 2006 | December 2010 |
| NCT00193180 | Completed | Phase 2 | Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer | May 2005 | January 2009 |
| NCT01137916 | Completed | Phase 2 | Study to Evaluate Imatinib in Desmoid Tumors | June 2010 | December 2016 |
| NCT06175702 | Not yet recruiting | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL | December 25, 2023 | December 25, 2030 | |
| NCT04688983 | Not yet recruiting | Phase 2 | Study in Adult Ph-positive ALL | January 2021 | January 2026 |
| NCT06119789 | Not yet recruiting | Phase 2 | Precision Cancer Therapy in Rare Cancers | August 2024 | August 2033 |
| NCT05367765 | Not yet recruiting | Phase 4 | A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | April 30, 2022 | April 30, 2028 |
| NCT05895942 | Recruiting | Exploring the Molecular Mechanism Based on KIT Mutation | September 10, 2021 | September 10, 2025 | |
| NCT04877522 | Recruiting | Phase 4 | Asciminib Roll-over Study | August 30, 2022 | August 30, 2027 |
| NCT06090669 | Recruiting | Phase 1 | Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency | December 19, 2023 | October 30, 2027 |
| NCT06219733 | Recruiting | Phase 2 | Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | November 23, 2021 | September 15, 2029 |
| NCT05816785 | Recruiting | Early Phase 1 | Pilot Study of Imatinib Cetuximab Combo for H & N Cancer | April 18, 2023 | September 2025 |
| NCT05493215 | Recruiting | Phase 2 | Imatinib TDM in GIST | March 26, 2024 | December 2025 |
| NCT05413915 | Recruiting | Phase 3 | Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML | June 19, 2023 | December 2025 |
| NCT05071482 | Recruiting | Phase 4 | Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL | September 16, 2021 | October 30, 2025 |
| NCT04598009 | Recruiting | Phase 2 | Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | March 3, 2021 | March 31, 2026 |
| NCT02611492 | Recruiting | Phase 3 | A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults | April 2016 | December 2025 |
| NCT04933669 | Recruiting | Phase 2 | Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors | September 7, 2021 | December 31, 2029 |
| NCT04838041 | Recruiting | Phase 2 | Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation | November 11, 2021 | July 2029 |
| NCT06061094 | Recruiting | Phase 2 | Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT | July 14, 2023 | July 1, 2029 |
| NCT02326311 | Recruiting | Phase 3 | Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response | June 10, 2015 | December 31, 2023 |
| NCT02735707 | Recruiting | Phase 3 | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | April 11, 2016 | February 2028 |
| NCT05245968 | Recruiting | Phase 1 | A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) | December 1, 2021 | December 2025 |
| NCT00044304 | Recruiting | Phase 2 | Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome | September 26, 2002 | January 1, 2026 |
| NCT06336395 | Recruiting | Phase 2 | Ma-Spore ALL 2020 Study | March 4, 2020 | March 2030 |
| NCT04307576 | Recruiting | Phase 3 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | July 13, 2020 | June 30, 2032 |
| NCT05220280 | Recruiting | Phase 4 | SOLIDARITY Finland Plus Long-COVID | February 6, 2022 | December 2025 |
| NCT06051409 | Recruiting | Phase 3 | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. | August 31, 2023 | October 31, 2028 |
| NCT00585221 | Terminated | Phase 2 | Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients | July 2007 | July 2009 |
| NCT00115739 | Terminated | Phase 2 | Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma | February 2004 | August 2010 |
| NCT00320190 | Terminated | Phase 2 | Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib | August 2006 | January 2010 |
| NCT00362466 | Terminated | Phase 3 | A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy | April 2007 | June 2008 |
| NCT00402662 | Terminated | Phase 2 | A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma | February 2006 | June 2006 |
| NCT00415857 | Terminated | Phase 2 | Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R) | December 2006 | September 2013 |
| NCT00421317 | Terminated | Phase 2 | Imatinib in Adult Patients With Metastatic Ocular Melanoma | December 2005 | March 2007 |
| NCT00519090 | Terminated | Phase 3 | Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | October 2007 | October 2008 |
| NCT00751036 | Terminated | Phase 3 | Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg | June 2009 | August 2012 |
| NCT00812240 | Terminated | Phase 3 | Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) | January 2009 | July 2018 |
| NCT01117987 | Terminated | Phase 3 | Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) | April 2010 | April 2014 |
| NCT01392495 | Terminated | Phase 3 | Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) | June 2011 | March 2014 |
| NCT02146846 | Terminated | Population Pharmacokinetics of Imatinib in CML Patients in Iran | October 2012 | July 2017 | |
| NCT02174445 | Terminated | Phase 3 | An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years | March 2014 | October 2019 |
| NCT02462538 | Terminated | Phase 1/Phase 2 | Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL | November 3, 2015 | November 3, 2021 |
| NCT02685046 | Terminated | Phase 2 | Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy | April 2016 | September 1, 2019 |
| NCT03343600 | Terminated | Phase 2 | Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation | November 9, 2017 | August 31, 2019 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT00149136 | Unknown status | Phase 2 | Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. | August 2002 | |
| NCT03697668 | Unknown status | Phase 2 | Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites | September 17, 2017 | December 31, 2019 |
| NCT03515018 | Unknown status | Phase 3 | Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients | May 1, 2018 | May 1, 2020 |
| NCT02894645 | Unknown status | Phase 4 | Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | October 2008 | |
| NCT02638428 | Unknown status | Phase 2 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | December 2015 | December 2023 |
| NCT02602314 | Unknown status | Phase 4 | Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia | November 11, 2016 | February 2024 |
| NCT02576080 | Unknown status | Phase 3 | Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index | October 2015 | October 2020 |
| NCT02461849 | Unknown status | Phase 2 | Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy | April 4, 2014 | December 2022 |
| NCT02363361 | Unknown status | Phase 2 | Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study | April 2018 | December 2021 |
| NCT02317159 | Unknown status | Phase 4 | Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia | February 2015 | July 2017 |
| NCT02013089 | Unknown status | N/A | A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study | December 2013 | December 2017 |
| NCT01804985 | Unknown status | Phase 2 | De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia | December 2013 | May 2018 |
| NCT01782508 | Unknown status | Phase 2 | A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma | August 2012 | December 2014 |
| NCT00180921 | Unknown status | Phase 2 | Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck | July 2004 | |
| NCT03844360 | Unknown status | Phase 4 | Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease | January 31, 2016 | December 31, 2021 |
| NCT01503502 | Unknown status | Phase 2 | A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | August 2011 | December 2014 |
| NCT01491763 | Unknown status | Phase 4 | Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE | January 2008 | December 2022 |
| NCT00573326 | Unknown status | Phase 2 | Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement | February 2009 | June 2010 |
| NCT00327262 | Unknown status | Phase 3 | Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase | January 2004 | December 2008 |
| NCT00199186 | Unknown status | Phase 2 | Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) | March 2002 | |
| NCT01568645 | Withdrawn | Phase 1 | Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease | March 2, 2012 | December 11, 2012 |
| NCT01188889 | Withdrawn | Phase 1/Phase 2 | RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. | September 2013 | December 2017 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Gleevec
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2001
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2001
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Bcr-Abl
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Kit
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- CML
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- GIST
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- Ph+ALL